Compare Bristol-Myers Squibb Co (BMY) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares International Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.52 (market cap $116.30B), while iShares International Treasury Bond ETF trades at $40.88. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares International Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | IGOV | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $43.09 |
52-Week Low | $42.60 | $40.54 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IGOV trades at $40.58, down 0.64% with a bearish technical signal from moving averages and oscillators. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights downside risks from global inflationary pressures affecting its bond holdings. Support and resistance cluster tightly around $41, indicating a critical price zone.
Outlook remains cautious due to high duration exposure amplifying capital losses in rising rate environments. Investment opportunities are limited by macroeconomic headwinds, while risks include prolonged energy issues and geopolitical tensions impacting performance. Fundamental clarity is needed for a positive reassessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
